Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds…
X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)
X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®. This DMF covers the Chemistry, Manufacturing and…
Sunrise Oncology Centre Introduces Comprehensive Cancer Care in Vasai, a First for Palghar District
Sunrise Oncology Centre, a leading provider of comprehensive cancer care, is proud to announce the opening of its new facility in Vasai, marking the establishment of the first cancer registry in Palghar district. The new centre aims to provide holistic…
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the…
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS)…
Danone North America Announces the FDA’s Decision on Their Petition for the First-Ever Qualified Health Claim for Yogurt, Linking This Dairy Aisle Staple to a Reduced Risk of Type 2 Diabetes
In response to a petition submitted by food and beverage leader Danone North America, the U.S. Food and Drug Administration (FDA) today announced the first-ever qualified health claim for yogurt, recognizing a potential link between its regular consumption and a reduced…
Gateways Hospital and Mental Health Center Opens New Sensory Room, Providing Vulnerable Clients with Innovative, Client-Centered Care
Gateways Hospital and Mental Health Center unveiled its groundbreaking Sensory Room, a pioneering addition to acute patient care in Los Angeles, generously funded by a $45,000 grant from the Robert Ellis Simon Foundation. This innovative space signifies Gateways’ commitment to implementing client-centered approaches,…
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the…
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical…
New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils
Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL)…
